Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:59 PM
Ignite Modification Date:
2025-12-24 @ 7:59 PM
NCT ID:
NCT07005804
Eligibility Criteria:
Inclusion Criteria - Acute forms of CPPD: retrospective part of the study
* Cases included in the COLCHICORT cohort (NCT03128905), for whom this was the first acute episode of CPPD
Inclusion Criteria - Chronical forms of CPPD : prospective part of the study
* Patients affiliated to the French social security system
* Age ≥ 65 years
* Diagnosis of chronic CPPD (recurrent acute or persistent arthritis), meeting ACR/EULAR 2023,11 classification criteria after evaluation by a rheumatologist in the rheumatology department
* Progression of CPPD rheumatism for at least 3 months and still active CPPD rheumatism, defined by a visual analogue scale (VAS) of disease activity ≥ 40 and/or presentation of at least 1 crisis over the last 3 months
* Glomerular Filtration Rate (GFR) in Chronic Kidney Disease Epidemiology (CKD EPI Collaboration) ≥ 30ml/min/1.73m2
* Minimum time between the last intake of a crisis treatment and inclusion in the study, depending on their half-life, in order to not interfere with the results of the omics analyses: 2 weeks (Nonsteroidal Anti-Inflammatory Drugs Per Os (PO) or Intramuscular (IM) or Intravenous (IV); corticosteroids PO or IV; colchicine PO; anakinra Subcutaneous (SC), 1 month (methotrexate PO, tocilizumab SC), 3 months (canakinumab SC, tocilizumab IV)
* Signed written consent for study participation
Exclusion Criteria - Acute forms of CPPD:
* Missing data concerning transcriptomic and metabolomic analyses.
* Opposition
Exclusion Criteria - For chronic forms of CPPD:
* History of gout or presence of monosodium urate (MSU) crystals on joint fluid,
* Cognitive decline (confusion and neurodegenerative diseases)
* Inability to provide informed consent and disease VAS
* Patient under guardianship or curatorship
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
65 Years
Study:
NCT07005804
Study Brief:
Protocol Section:
NCT07005804